Sarah Wordsworth

Has grant

Professor

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Sarah Wordsworth is a faculty member at the University of Oxford, located in the United Kingdom. Her research focuses on health economics, particularly in the areas of cost-effectiveness analysis and personalized medicine strategies. Recent publications include studies on DPYD testing in metastatic breast cancer and screening strategies for maturity-onset diabetes of the young across Europe.

Recent Grants

Grant: Close

Economic evaluation of multi-cancer early detection test

Open Date: 2022-10-01

Close Date: 2023-09-01

Grant: Close

The Integration and Analysis of Data using Artificial Intelligence to Improve Patient Outcomes with Thoracic Diseases

Open Date: 2021-09-01

Close Date: 2025-09-01

Grant: Close

Integrative Translational Research in Primary Immunodeficiency

Open Date: 2020-10-01

Close Date: 2025-10-01

Grant: Close

Health Protection Research Unit, Infectious Disease. £4 million. National Institute for Health Research

Open Date: 2020-09-01

Close Date: 2025-09-01

Grant: Close

Evaluation and Transfer of mobile whole slide tissue scanners and liquid biopsies to deliver fast and precise diagnosis for improved outcomes of children and young adults with EBV-driven lymphoma: a joint Tanzanian and Ugandan Paediatric Oncology Network Initiative

Open Date: 2019-06-01

Close Date: 2024-06-01

Articles (12)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (15)

James Davies

University of Oxford

UNITED KINGDOM

Sarah Wordsworth

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (12)

Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies

Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK

Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries

Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation

Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems

Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial

Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib

Cost–effectiveness of Alternative NTRK Testing Strategies in Cancer Patients Followed by Histology-Independent Therapy with Entrectinib: an Analysis of Three European Countries

HEcoPerMed, Personalized Medicine from a Health Economic Perspective: Lessons Learned and Potential Opportunities Ahead

Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort study

Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features

Clinical utility of whole-genome sequencing in precision oncology

Collaborators (15)

James Davies

Melissa Dobson

Paul Moss

Apostolos Tsiachristas

Philip Law

Jianguo Zhuang

Matthijs Versteegh

Sarah Briggs

Alan Ramsay

Andrea Pepper

James Allan

Samantha Knight

Professor Jonathan C Strefford

Maureen P. M. H. Rutten-van Mölken

Richard Rosenquist

Make your next move.